Apollo Consulting and Trading AG Partner for Biotech JVs and IPO
• Legal counseling for build-up of global bio-surfactant production capacity
• Two-digit million Euros JVs in animal feed, fertilizer and detergent sectors
(firmenpresse) - Zurich (Switzerland), March 29, 2017 – Apollo Consulting & Trading AG advised Swiss-based biotechnology company Biotensidon International AG in all legal matters concerning the build-up of international production capacity for rhamnolipids (natural surfactants). These activities include drafting the company’s IPO strategy and acting as lead consultancy for setting up strategic joint ventures of a German Biotensidon subsidiary with leading key players in their respective industries, among others with global and European market leaders in animal feed production, in the fertilizer industry and the detergents sector.
Biotensidon has recently achieved a biotechnological breakthrough and is now the first company in the world to be able to mass-produce microorganism-based rhamonlipid bio-surfactants on an industrial scale. Until recently, the global rhamnolipds market was characterized by extremely high prices and too-low-to- matter quantities of rhamnolipids, due to limited mass-production know-how. Biotensidon’s breakthrough and its current investments in production capacity for 2.000 tons by 2018 will change this situation. As demand for bio-surfactants will soar in the upcoming years, Biotensidon is likely to be instrumental in building the global commercial market for rhamnolipids.
From the beginning of the project, Apollo’s partner Mr. Mark Gössel was part of Biotensidon’s integrated JV team and was involved in drafting appropriate strategies for the multi-million Euro deals and the initial public offering (IPO), which is set to take place at Zurich Stock Exchange in 2017. Providing insight in relevant aspects of corporate and tax law, Mr. Gössel was influential in planning the JVs’ structure. He also led negotiations with Biotensidon’s JV partners and served on the due diligence task force.
- Ends -
Themen in dieser Pressemitteilung:
mark-goessel-lawyer
ceo-apollo-ag
law-firm
international-legal-counseling
biotechnology
joint-ventures
ipo-strategy
Unternehmensinformation / Kurzprofil:
PresseKontakt / Agentur:
Mark Gössel
CEO Apollo Consulting AG Zurich (Switzerland)
Tel.: +41 43 317 12 06
email: mark.goessel(at)apollo.ag
Datum: 29.03.2017 - 09:13 Uhr
Sprache: Deutsch
News-ID 533059
Anzahl Zeichen: 2057
contact information:
Contact person: Mark Gössel, CEO
Town:
Zollikon
Phone: +41 43 317 12 06
Kategorie:
Business News
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 29.03.2017
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apollo Consulting and Trading AG Partner for Biotech JVs and IPO"
steht unter der journalistisch-redaktionellen Verantwortung von
Apollo Consulting & Trading AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
